The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2

Objectives On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19). Methods From February 6, 2022 to April 2, 2022, the incidence of COVID...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hanul Park, Young Joon Park, Hye Young Lee, Mi Yu, Yeong-Jun Song, Sang Eun Lee, Ji-Joo Lee, Eun-Sol Lee, Yeonjung Kim
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Korea Disease Control and Prevention Agency 2022-12-01
Colecção:	Osong Public Health and Research Perspectives
Assuntos:	covid-19 effectiveness of vaccine omicron variant paxlovid
Acesso em linha:	http://ophrp.org/upload/pdf/j-phrp-2022-0262.pdf
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!